Neurocrine Biosciences
San Diego-based medical organization developing therapies for brain-related diseases.
Founded
1992San Diego-based medical organization developing therapies for brain-related diseases.
Neurocrine Biosciences, Inc., founded in San Diego, California, is dedicated to discovering, developing, and marketing pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's mission is to alleviate patient suffering through innovative treatments. Their product portfolio includes INGREZZA and DYSVAL for tardive dyskinesia, and ONGENTYS as an adjunctive therapy for Parkinson's disease. Neurocrine also focuses on treatments for endometriosis and uterine fibroids, with ongoing clinical programs in various therapeutic areas.
Notable figures associated with Neurocrine include its leadership team and key investors who have supported its growth. The company has achieved significant milestones, such as the successful commercialization of its flagship products, which have had a substantial impact on patient care. Neurocrine's contributions to medical science have positioned it as a leader in the biopharmaceutical industry, particularly in the realm of brain-related diseases.
Companies similar to Neurocrine Biosciences include Crinetics Pharmaceuticals, Neurolixis, Acadia Pharmaceuticals and Synchroneuron.
Neurocrine Biosciences was founded in 1992.
Neurocrine Biosciences' headquarters is located in San Diego, CA, US.
Neurocrine Biosciences' most recent funding round was for $250M (USD) in February 2015.
As of Feb 19, 2015, Neurocrine Biosciences has disclosed funding of $260M (USD). Undisclosed round amounts are excluded.
Neurocrine Biosciences has 1,200 employees as of Feb 6, 2024.
Synchroneuron
synchroneuron.com
